Alpha Tau Medical has reported positive interim results from the first-in-human REGAIN study of its Alpha diffusing alpha-emitters radiation therapy (DaRT), achieving an overall response rate of 100% among evaluable patients in recurrent glioblastoma (GBM).

The interventional, prospective, open-label, single-arm study (NCT06910306) is assessing the safety and feasibility of intratumoral treatment in up to 20 US patients with non-resectable tumours following prior radiation.

Clinicians at the Ohio State University Comprehensive Cancer Center – James delivered the therapy using minimally invasive burr-hole access and real-time neuronavigation, avoiding open craniotomies across all eight treated patients.

Addressing primary feasibility and safety endpoints, investigators deployed planned sources successfully in every participant, recording no unanticipated serious adverse events (AEs) or permanent procedure-related symptoms as of 11 November.

All eight patients remain alive, with median overall survival (OS) not yet reached after a median follow-up of 6.9 months among the six evaluable participants, five of whom achieved complete responses.

One individual recorded a partial response with a 58% tumour reduction. Follow-up scans revealed asymptomatic or suspected radiation necrosis in four patients, while two individuals require further imaging to assess necrosis versus suspected progression.

Alpha Tau CEO Uzi Sofer said: “In May we shared the first three patients treated with Alpha DaRT in the brain. Six months later, we see how truly transformational Alpha DaRT could be for recurrent GBM. Eight patients have been treated, every procedure has gone as planned, and every one of those patients is alive.

“The trial thus far has exceeded our wildest expectations, particularly in such a difficult cancer. GBM is one of the most devastating diagnoses in oncology, and recurrence is virtually inevitable.

“We look forward to following these patients’ progress as their scans mature, and to continuing enrolment toward 20 patients, which we believe, based on initial discussions, may support market submission requirements for Alpha DaRT in patients with this disease.”

Tel Aviv University researchers originated the diffusing alpha-emitter technology, which Alpha Tau Medical, founded in 2016, is developing to destroy solid tumours while sparing adjacent healthy brain tissue.

In September 2024, the FDA approved Alpha Tau Medical’s investigational device exemption (IDE) application to evaluate Alpha DaRT in immunocompromised patients with recurrent cutaneous squamous cell carcinoma (cSCC).